N-bromobutanimide → 4-(3-bromo-1-(4-methoxyphenyl)-1H-indol-2-yl)-3,5-dimethylisoxazole

HRID 241623Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 241623
C1C(=O)N([Br:8])C(=O)C1.[CH3:9][O:10][C:11]1[CH:16]=[CH:15][C:14]([N:17]2[C:25]3[C:20](=[CH:21][CH:22]=[CH:23][CH:24]=3)[CH:19]=[C:18]2[C:26]2[C:27]([CH3:32])=[N:28][O:29][C:30]=2[CH3:31])=[CH:13][CH:12]=1>CN(C=O)C>[Br:8][C:19]1[C:20]2[C:25](=[CH:24][CH:23]=[CH:22][CH:21]=2)[N:17]([C:14]2[CH:13]=[CH:12][C:11]([O:10][CH3:9])=[CH:16][CH:15]=2)[C:18]=1[C:26]1[C:27]([CH3:32])=[N:28][O:29][C:30]=1[CH3:31]

Komponenten

4

Versuchsvorschrift

NBS (59 mg, 0.33 mmol) was added to a cooled (0° C.) solution of 4-(1-(4-methoxyphenyl)-1H-indol-2-yl)-3,5-dimethylisoxazole (105 mg, 0.33 mmol) in 5 ml of DMF. The temperature was allowed to warm to RT and the mixture was stirred at RT for 30 min. DMF was evaporated. DCM and water were added and the phases were separated. After evaporation of the solvents, the residue was purified by flash chromatography with heptane/EtOAc 9:1 to provide 4-(3-bromo-1-(4-methoxyphenyl)-1H-indol-2-yl)-3,5-dimethylisoxazole in 98% yield. ES/MS m/z: 365.14 (M+H), 363.30 (M−H).

Aufarbeitung

  1. customDMF was evaporated
  2. additionDCM and water were added
  3. customthe phases were separated
  4. customAfter evaporation of the solvents
  5. customthe residue was purified by flash chromatography with heptane/EtOAc 9:1

Quellen und Nachweise

ORD-Eintrag
ord-b7ae562d125b49d18c43b1e96e1de755
Quelldatensatz
uspto-grants-2014_02
Patentnummer
US08653072B2

Notizen zur Reaktion

Wird geladen…